Amphastar Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Amphastar Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 1, 2026, to elect directors, ratify auditors, and vote on executive compensation.
NASDAQ
Amphastar Pharmaceuticals has scheduled its 2025 Annual Meeting for June 2, 2025, and is seeking stockholder votes on the election of directors, ratification of auditors, executive compensation, and amendments to the company's certificate of incorporation.
NASDAQ
Amphastar Pharmaceuticals will hold its 2025 annual meeting virtually on June 2, 2025, to vote on director elections, auditor ratification, executive compensation, and amendments to the certificate of incorporation.
NASDAQ
Amphastar Pharmaceuticals issues a supplement to its proxy statement to correct an error in the voting standard for the proposed amendment and restatement of its 2015 Equity Incentive Plan.
NASDAQ
Amphastar Pharmaceuticals has filed a definitive proxy statement with the SEC.
NASDAQ
Amphastar Pharmaceuticals is holding its annual meeting to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to its equity incentive plan.